News

Industry welcomes Myriad verdict
Enlarge image

RegulatoryGermanySwitzerland

Industry welcomes Myriad verdict

17.06.2013 - Industry organisations and biotech experts have welcomed the vote of the US Supreme Court to allow cDNA to be patented.

In a groundbreaking verdict, the nine judges of the highest Court of the United States said that DNA generally cannot be patented because it occurs in nature. However judge Clarence Thomas added that cDNA is made by man and thus can be patented by biotech firms. 

The vote in the case Myriad Genetics vs the American Society for Pathology is a well-balanced compromise.  Researchers had argued that Myriad Genetics’ current practice to prohibit any isolation of BRCA1 and BRAC2 gene sequences predictive for breast or ovarian cancer hampered research and innovation. Companies and pharma organisations told European Biotechnology News, the verdict was good news for the industry as most biotech patents include claims on modified DNA sequences not occurring in nature. 

„Roche welcomes that the US Supreme Court confirmed that cDNA is patent-eligible“, a spokesman told EuroBiotechNews.„IP on our medicaments and diagnostics mostly is not based on naturally occurring DNA.“ Sigfried Throm from the German pharma association vfa confirmed: „The verdict does not affect drugs made by genetically engineering as they are systematically modified compared to their natural counterpart." Diagnostics expert Joerg Hollidt, CEO of IVD firms in.vent Diagnostica and DRDx said that the decision will foster patenting of cDNA and technology claims. "The decision cannot and will not stop the development of personalised medicine or personalised diagnostics“, stressed Hollidt. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/industry-welcomes-myriad-verdict.html

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

M&AIreland

08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.

BusinessIreland

07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • KAROLINSKA (S)12.95 SEK8.37%
  • IXICO (UK)35.50 GBP5.97%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • MEDIGENE (D)9.65 EUR-10.32%
  • SERODUS (N)3.08 NOK-8.88%
  • ZELTIA (E)3.69 EUR-8.44%

TOP

  • IXICO (UK)35.50 GBP57.8%
  • DBV TECHNOLOGIES (F)75.75 EUR45.7%
  • ADOCIA (F)88.67 EUR38.5%

FLOP

  • BIOTEST (D)25.26 EUR-63.9%
  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • BIOTECH PHARMACON (N)9.44 NOK-45.4%

TOP

  • ADOCIA (F)88.67 EUR533.8%
  • FORMYCON (D)28.20 EUR311.7%
  • VERONA PHARMA (UK)4.88 GBP306.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEOVACS (F)1.05 EUR-70.1%
  • BIOTEST (D)25.26 EUR-69.2%

No liability assumed, Date: 28.07.2015